Sign In

Kshitij Srivastava

Enabling personalised cancer immunotherapy

Kshitij Srivastava is a seasoned Immuno-Oncologist with a passion for Business Development, boasting expertise in NGS, Biomarker, and CDx solutions for Clinical Immuno-Oncology.

With over 7 years of experience in translational oncology research, Kshitij holds an exceptional publication record with lead author contributions in prestigious journals such as 'Cancer Cell' and 'Science'.

His professional journey includes project leadership roles in major biotech companies, where he effectively managed interdisciplinary drug discovery teams.

Kshitij Srivastava excels in building strong relationships within the Oncology Key Opinion Leader (KOL) network and demonstrates proficiency in networking, business development, and scientific sales.

His educational background is highly diverse, encompassing studies in Business Administration, Pharmacy, Biology, Genetics, and Veterinary Science from renowned institutions like Ucl, Dkfz German Cancer Research Center, Karolinska Institutet, and Heidelberg University.

His professional experience includes roles at esteemed organizations such as Bayer, Personalis, Inc., Novoptim, Evotec, Merck Serono, and the Dkfz German Cancer Research Center, where he served as a Helmholtz Postdoctoral Fellow and a Graduate Student.

Moreover, Kshitij's skills extend to Strategy and Business Consulting, Field Application Science, and Research in In Vivo Pharmacology, culminating in a well-rounded professional profile.

Kshitij Srivastava's innate curiosity and expertise make him a valuable asset in the field of Immuno-Oncology and Business Development.

Highlights

Oct 13 · linkedin

Curative therapies, yes that is how I see the potential of Cell and Gene Therapy. It is estimated that there are more than 6000 monogenic diseases (diseases caused by mutations in single genes that a person is born with) affecting over 350 million people worldwide. While these ‘living drugs’, hold immense potential for treating such diseases, their development comes with its own set of challenges. This fall, we will be sharing key considerations and strategic learnings across a wide array of topics (Preclinical development, Clinical Biomarker strategy, CDx) in a 3-part series.   Please come and join us with your questions as cross-industry collaboration is truly needed to ensure that these innovative therapies reach patients rapidly by overcoming development challenges. In the first Webinar, industry experts will be sharing insights for driving acceleration of preclinical gene therapy programs to IND/CTA and beyond. #CGT #CellandGeneTherapy #Biomarkers #RareDiseases #Genetics #PrecisionMedicine #CellTherapy #GeneTherapy #labcorp

Feb 14 · linkedin

Really humbled to share the recognition and promotion to Senior Director Business Development - Precision Medicine role at Labcorp Drug Development! #drugdevelopment #Biomarkers #clinicaltrials #teamwork #precisionmedicine #oncology #science

Related Questions

What are Kshitij Srivastava's main responsibilities at Labcorp?
How did Kshitij Srivastava transition from a career in software engineering to business development in precision medicine?
What projects has Kshitij Srivastava worked on at Labcorp?
What is Kshitij Srivastava's educational background?
How has Kshitij Srivastava's experience at Uber and ORNL influenced his career?
Kshitij Srivastava
Kshitij Srivastava, photo 1
Kshitij Srivastava, photo 2
Add to my network

Location

Cologne Bonn Region